Testing a new cancer-fighting medicine combined with standard treatments

This trial is testing a new medicine called GSK5764227 that works by delivering a toxin directly into cancer cells to destroy them while leaving healthy cells alone. Researchers will combine GSK5764227 with standard cancer treatments you may already be receiving. The study will check whether the medication is safe, how your body processes it, whether it triggers helpful immune responses, and whether it can shrink or slow your cancer.

Current cancer treatments don't always work well enough for advanced colorectal and prostate cancers, and they can affect healthy cells and cause side effects. This trial is exploring whether this new approach—which aims to target cancer cells more precisely—could improve outcomes when used alongside treatments you're already getting.